Meningococcal polysaccharide vaccine group Y

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Meningococcal polysaccharide vaccine group Y
Accession Number
DB13888
Description

Meningococcal group Y polysaccharide is group-specific polysaccharide antigens extracted and purified from Neisseria meningitidis serogroup Y. N. meningitidis is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y.

Type
Biotech
Groups
Approved, Experimental, Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • Meningococcal polysaccharide antigen group Y
  • Neisseria meningitidis group Y capsular polysaccharide antigen
  • Neisseria meningitidis group Y polysaccharide antigen, A

Pharmacology

Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
MenhibrixMeningococcal polysaccharide vaccine group Y (5 ug/0.5mL) + Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (2.5 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (5 ug/0.5mL)Injection, powder, lyophilized, for solutionIntramuscularGlaxoSmithKline Biologicals SA2013-09-032013-11-27Us
MenhibrixMeningococcal polysaccharide vaccine group Y (5 ug/0.5mL) + Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen (2.5 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (5 ug/0.5mL)KitIntramuscularGlaxoSmithKline Biologicals SA2013-09-032017-09-17Us
Menomune - A/c/y/w-135 CombinedMeningococcal polysaccharide vaccine group Y (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group A (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group W-135 (50 ug/0.5mL)SubcutaneousSanofi Pasteur Inc.1981-11-232017-09-10Us
Menomune-A/c/y/w-135Meningococcal polysaccharide vaccine group Y (500 mcg) + Meningococcal polysaccharide vaccine group A (500 mcg) + Meningococcal polysaccharide vaccine group C (500 mcg) + Meningococcal polysaccharide vaccine group W-135 (500 mcg)Powder, for solutionSubcutaneousSanofi Pasteur Limited1983-12-312017-04-05Canada
Menomune-A/c/y/w-135Meningococcal polysaccharide vaccine group Y (50 mcg) + Meningococcal polysaccharide vaccine group A (50 mcg) + Meningococcal polysaccharide vaccine group C (50 mcg) + Meningococcal polysaccharide vaccine group W-135 (50 mcg)Kit; Powder, for solutionSubcutaneousSanofi Pasteur Limited1993-10-292017-04-05Canada
Menomune-A/c/y/w-135Meningococcal polysaccharide vaccine group Y (2.5 mg) + Meningococcal polysaccharide vaccine group A (2.5 mg) + Meningococcal polysaccharide vaccine group C (2.5 mg) + Meningococcal polysaccharide vaccine group W-135 (2.5 mg)Powder, for solutionSubcutaneousAventis Pasteur Limited1998-08-132006-07-17Canada
MenveoMeningococcal polysaccharide vaccine group Y (5 mcg/0.5mL) + Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine (3.3-33.3 mcg/0.5mL) + Meningococcal polysaccharide vaccine group A (10 mcg/0.5mL) + Meningococcal polysaccharide vaccine group C (5 mcg/0.5mL) + Meningococcal polysaccharide vaccine group W-135 (5 mcg/0.5mL)Powder, for solution; SolutionIntramuscularGlaxosmithkline Inc2010-07-29Not applicableCanada
NimenrixMeningococcal polysaccharide vaccine group Y (5 mcg) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (44 mcg) + Meningococcal polysaccharide vaccine group A (5 mcg) + Meningococcal polysaccharide vaccine group C (5 mcg) + Meningococcal polysaccharide vaccine group W-135 (5 mcg)Kit; Powder, for solutionIntramuscularPfizer Canada Ulc2013-08-22Not applicableCanada

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
CBZ4BH7TJ1
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347911457
RxNav
314725
FDA label
Download (83.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingPreventionPapillomavirus Infections1
4CompletedBasic ScienceBloodstream Infections / Meningitis / Meningococcal Disease1
4CompletedPreventionDiphtheria / Meningococcal / Pertussis Diseases / Streptococcal / Tetanus1
4CompletedPreventionMeningococcal Disease1
4CompletedTreatmentImmunizations / Meningitis / Pertussis / Preventive Immunization; Meningitis1
4RecruitingOtherHuman Immunodeficiency Virus (HIV) Infections / Meningococcal Meningitis1
4RecruitingOtherMeningococcal Meningitis1
4RecruitingPreventionMeningococcal Disease, Invasive1
3CompletedPreventionBacterial Infections / Neisseria Meningitidis / Virus Diseases1
3CompletedPreventionBloodstream Infections / Meningitis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntramuscular
KitIntramuscular
Kit; powder, for solutionSubcutaneous
Powder, for solutionSubcutaneous
Powder, for solution; solutionIntramuscular
Kit; powder, for solutionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on September 08, 2017 14:22 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates